The FDA has cleared golimumab, a rheumatoid arthritis drug to be sold by Johnson & Johnson and Schering-Plough under the brand Simponi. The treatment, which requires fewer injections than J&J's blockbuster drug Remicade, also gained U.S. approval for use in psoriatic arthritis and a form of spinal arthritis called ankylosing spondylitis.

Related Summaries